We use cookies and similar technologies to run this website. See Terms and Conditions.

Online education for healthcare professionals
Physician's chats
Pharmacist's chats

Probiotics: Oral and Vaginal

Probiotics: Oral and Vaginal
Published Wednesday 15 June 2022

Probiotics not for digestion only

Probiotics are widely used for prevention and rehabilitation of gastrointestinal disorders. However in recent decades effective probiotics of another concept have appeared - for example, vaginal or oral. This article is intended to teach how to tell pharmacy visitors about them.

Oral probiotics

According to modern data, probiotics are live microorganisms that, when administered in adequate amounts, have a beneficial effect on human health1,2.

Nowadays probiotics are offered as over-the-counter drugs and dietary supplements. It should be noted that a modern probiotic should include an effective combination of microorganisms with proven probiotic properties - that is, produce biologically active agents to suppress pathogens, be able to colonize to let them become temporary (for treatment period) or permanent inhabitants of the vagina, oral cavity or other microecologies.2,3 To be effective, the drug must also be stable, acid-resistant (when taken orally) and retain viable bacteria during a long shelf life4.

Correcting balanced microflora of the oral cavity is one of the promising areas for probiotics use. Many human diseases can be associated directly (for example, caries, periodontal disease and oral candidiasis) or indirectly (cardiovascular diseases) with occuring imbalance of the oral microbiota2.

Professor Peter van der Bijl (South Africa) states in his review “Relationship between periodontal disease and cardiovascular system”, “Numerous observational (case-control, cohort, cross-sectional), epidemiological and invasive studies support the relation between clinically diagnosed periodontal disease and CAD”. In 2021, an American Heart Association (AHA) task team conducted an electronic literature search on the association between periodontal disease and cardiovascular disease (excluding infective endocarditis), Behçet’s syndrome, Stevens-Johnson’s syndrome, and Sjögren’s syndrome. A total of 537 articles were analyzed in dental/periodontal (61%) and medical (39%) journals. It was concluded that “periodontal disease is related to atherosclerosis, regardless of somatic pathology”, although a direct correlation was not found. Professor van der Bijl suggests that the inflammation associated with periodontal disease may be both a part of pathobiology of atherogenesis and a trigger for plaque rupture.

Oral probiotics are a new generation of probiotic strains evolved from the oral microbiota with extremely low pathogenic potential5. Nowadays, salivarcin-producing probiotics (Streptococcus salivarius M18 and K12) are considered as caries and periodontal diseases prevention, and their potential in bacteriotherapy for dental caries is being researched2,5.

Mechanism of action: producing local antibacterial substances (salivarcins), they normalize oral cavity microbiota without affecting the normal flora adversely5. The M18 strain also produces the enzymes dextranase and urease, which reduce plaque buildup and neutralize oral acidity.

Use: to maintain a healthy balance of oral microflora.

Benefits:

  • prevent oral dysbiosis, reduce plaque as well, eliminate unpleasant odors;
  • prevent caries, in young children as well;
  • prevent gingivitis and periodontitis;
  • prevent caries when using braces.

Vaginal probiotics

Another probiotic application area is the problem of vaginal infections in women due to their high prevalence, insufficient effectiveness of antimicrobial therapy and the relapse risk. One of the solutions is prescribing modern combined probiotics strains based on lactobacilli obtained from the vaginal biotope of healthy women and protecting the vaginal environment against pathogens6,7,8.

Mechanism of action: protective functions are provided due to lactic and other organic acids, that maintain physiological pH level, production, ability to form a protective biofilm, counteract the adhesion of pathogens, as well as the production of antimicrobial substances (hydrogen peroxide, bacteriocins)8.

Use: to restore the physiological pH level and maintain vaginal microflora balance.

Benefits:

  • as the second stage of bacterial vaginosis, nonspecific vulvovaginitis, colpitis therapy;
  • prevent vulvovaginal candidiasis relapse;
  • prepare for planned gynecological operations;
  • treat atrophic vaginitis in postmenopause;
  • prepare pregnant women who are at risk for bacterial vaginosis.

Probiotic lactobacilli can be used both vaginally and orally. It should be noted that when taken orally, probiotics are more effective than vaginal forms, but require a longer intake8.

Today probiotics are considered very promising and require further clinical research. This means that pharmaceutical specialists need to be aware of action and use of modern probiotics in order to provide competent advice to pharmacy visitors.

References:

  1. Global practical recommendations of the World Gastroenterological Organization;
  2. Andreeva, I. V., Stetsyuk O.U. A new probiotic strain of Streptococcus salivarius K12 in clinical practice. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; V. 21; 2: 92-99.
  3. Potapov V.A. Probiotics in gynecology. Another fashion or a conscious need (analytical review. Z turbotoyu pro zhinku. 2015; 1: 10-15.
  4. Shikh E.V. Clinical and pharmacological aspects of oral lactobacilli preparations use in the treatment of vaginal dysbiosis. Obstetrics and gynecology: news, opinions, training. 2021; V. 9; 2: 82-91.
  5. Kiselnikova L.P., Toma E.I. Prospects for the use of probiotics to prevent caries and periodontal diseases in children. Effective pharmacotherapy. 2021; V. 17; 12: 24–28.
  6. Bairamova G.R., Andreev A.O., Dobrovolskaya D.A., Peremykina A.V. Violation of the microbiocenosis of the vagina and ways of its correction: the interaction of science and practice. Obstetrics and gynecology: news, opinions, training. 2021; V. 9; 1: 44-51.
  7. Dicke G.B. Bacterial vaginosis: new aspects of etiopathogenesis and choice of therapeutic strategies. PMZH. Mother and child. 2019; 2(4): 307-313.
  8. Leonova M.V. Probiotics in the treatment of vaginal infections: effectiveness with regard to evidence-based medicine. Medical advice. 2020; (13): 148-154.

 

Colleagues, haven't you joined our PharmaCourses of MENA region Telegram chats yet?

In the chats of more than 6,000 participants, you can always discuss breaking news and difficult situations in a pharmacy or clinic with your colleagues. Places in the chats are limited, hurry up to get there.

Telegram chat for pharmacists of MENA region: https://t.me/joinchat/V1F38sTkrGnz8qHe 

Telegram chat fo physicians of MENA region: https://t.me/joinchat/v_RlWGJw7LBhNGY0

Last article
Viral Respiratory Infections During COVID-19 Pandemic
30 September

Viral Respiratory Infections During COVID-19 Pandemic

Etiology, symptoms and therapy of acute respiratory tract infections

COVID-19: season 2022-2023
21 September

COVID-19: season 2022-2023

Experts' forecasts and the scenarios for epidemic course

Use of Antihistamines in Pediatrics
08 September

Use of Antihistamines in Pediatrics

Antihistamines for therapy of allergic diseases in children and adolescents

Most popular
Viral Respiratory Infections During COVID-19 Pandemic
30 September

Viral Respiratory Infections During COVID-19 Pandemic

Etiology, symptoms and therapy of acute respiratory tract infections

COVID-19: season 2022-2023
21 September

COVID-19: season 2022-2023

Experts' forecasts and the scenarios for epidemic course

Use of Antihistamines in Pediatrics
08 September

Use of Antihistamines in Pediatrics

Antihistamines for therapy of allergic diseases in children and adolescents

Latest news
MoHAP Discusses Ways to Improve Mental Health of School Students
06 October

MoHAP Discusses Ways to Improve Mental Health of School Students

MoHAP has organized a training workshop on school student’s mental health

Qatar Minister of Public Health Meets Lebanese Counterpart, Executive Director of Global Fund to Fight AIDS​​
06 October

Qatar Minister of Public Health Meets Lebanese Counterpart, Executive Director of Global Fund to Fight AIDS​​

During the meetings reviewed aspects of cooperation in the health fields

Oman Health Minister Takes Part in High-Level WHO Meeting
06 October

Oman Health Minister Takes Part in High-Level WHO Meeting

The meeting participants discussed the prevention and control of NCDs

Fill in this field

Fill in this field

Fill in this field

Fill in this field

Fill in this field

Fill in this field

Fill in this field

Fill in this field

Please enter the valid phone number

Fill in this field